Synchronized determination of sacubitril and valsartan with some co-administered drugs in human plasma via UPLC-MS/MS method using solid-phase extraction.
Biomed Chromatogr
; 35(11): e5203, 2021 Nov.
Article
en En
| MEDLINE
| ID: mdl-34145610
ABSTRACT
An accurate and sensitive UPLC-MS/MS method was developed and validated for the simultaneous estimation of the newly developed combination of sacubitril and valsartan and the co-administered drugs nebivolol, chlorthalidone and esomeprazole in human plasma. Solid-phase extraction was conducted for the purification and extraction of the drugs from human plasma. Chromatographic separation was carried out on an Agilent SB-C18 (1.8 µm, 2.1 × 50 mm) column using losartan as internal standard. Isocratic elution was applied using acetonitrile-0.1% formic acid in water (85 15, v/v) as mobile phase. Detection was carried out using a triple-quadrupole tandem mass spectrometer using multiple reaction monitoring, at positive mode at m/z 412.23 â 266.19 for sacubitril, m/z 436.29 â 235.19 for valsartan, m/z 405.8 â 150.98 for nebivolol, m/z 346.09 â 198 for esomeprazole and a selected combination of two fragments m/z 423.19 â 207.14 and 423.19 â 192.2 for losartan (internal standard), and in negative ionization mode at m/z 337.02 â 190.12 for chlorthalidone. The method was linear over the concentration ranges 30-2,000 ng/ml for sacubitril, 70-2,000 ng/ml for valsartan, esomeprazole and chlorthalidone and 70-5,000 pg/ml for nebivolol. The developed method is sensitive and selective and could be applied for dose adjustment, bioavailability and drug-drug interaction studies.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Compuestos de Bifenilo
/
Cromatografía Líquida de Alta Presión
/
Espectrometría de Masas en Tándem
/
Extracción en Fase Sólida
/
Valsartán
/
Aminobutiratos
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Año:
2021
Tipo del documento:
Article